Exelixis (EXEL) Cash from Investing Activities (2010 - 2026)
Exelixis (EXEL) recorded quarterly Cash from Investing Activities of -$51.1 million in Q2 2026, down 287.47% quarter-over-quarter from $27.2 million in Q1 2026, and down 202.62% on a YoY basis from $49.8 million in Q2 2025.
Exelixis (EXEL) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Exelixis' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$51.1 million for Q2 2026.
- In Q2 2026, Cash from Investing Activities fell 202.62% year-over-year to -$51.1 million; the TTM figure through Apr 2026 stood at $249.6 million (up 239.59% YoY), while the FY2026 annual figure was $350.4 million, up 400.08% from the prior year.
- Cash from Investing Activities was -$51.1 million for Q2 2026 at Exelixis, down from $27.2 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $248.0 million in Q3 2025 to a low of -$245.8 million in Q4 2022.
- Historically, Cash from Investing Activities has averaged -$21.7 million across 5 years, with a median of -$49.6 million in 2023.
- The sharpest annual moves came in 2022 and 2024: Cash from Investing Activities tumbled 1782.67% in 2022, then jumped 325.43% in 2024.
- A 5-year view of Cash from Investing Activities shows it stood at -$245.8 million in 2022, then surged by 125.12% to $61.7 million in 2023, then tumbled by 451.73% to -$217.1 million in 2024, then jumped by 111.7% to $25.4 million in 2025, then tumbled by 301.02% to -$51.1 million in 2026.
- The last three Cash from Investing Activities figures came in at -$51.1 million (Q2 2026), $27.2 million (Q1 2026), and $25.4 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 579,519.10 |
| 10 | Exelixis | 13.61 Bn | 12.83 Bn | 590.86 Mn | -51.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | -51.07 Mn |
| Apr 3, 2026 | -51.07 Mn |
| Jan 2, 2026 | 27.24 Mn |
| Jan 2, 2026 | 27.24 Mn |
| Oct 3, 2025 | 25.41 Mn |
| Oct 3, 2025 | 25.41 Mn |
| Jul 4, 2025 | 248.03 Mn |
| Jul 4, 2025 | 248.03 Mn |
| Apr 4, 2025 | 49.76 Mn |
| Apr 4, 2025 | 49.76 Mn |
| Jan 3, 2025 | -93.20 Mn |
| Jan 3, 2025 | -93.20 Mn |
| Sep 27, 2024 | -217.15 Mn |
| Sep 27, 2024 | -217.15 Mn |
| Jun 28, 2024 | 81.77 Mn |
| Jun 28, 2024 | 81.77 Mn |
| Mar 29, 2024 | 111.79 Mn |
| Mar 29, 2024 | 111.79 Mn |
| Dec 29, 2023 | 61.74 Mn |
| Dec 29, 2023 | 61.74 Mn |